Triple negative breast cancer is a distinct form of breast cancer that does not have estrogen receptors, progesterone receptors, or excess HER2 protein. These characteristics influence how the cancer may respond to treatment. Since hormone therapies and HER2 targeted therapies are generally not suitable for tumors without these targets, chemotherapy is often an important part of the treatment approach. The specific treatment plan depends on several clinical factors and is developed by a qualified oncology team.
Triple negative breast cancer, often called TNBC, can occur at different stages and may vary in size, grade, and biological behavior. Testing of the tumor helps healthcare professionals identify its characteristics and determine appropriate treatment options. Although TNBC does not respond to certain hormone or HER2 directed treatments, several treatment approaches may be considered depending on the individual situation.
Important factors that may influence treatment planning include:
Surgery is commonly considered for localized breast cancer and may involve breast conserving surgery or mastectomy, depending on the clinical situation. Radiation therapy may also be recommended in some cases. For certain patients, systemic treatments such as chemotherapy or immunotherapy may be used as part of a broader treatment plan.
Chemotherapy uses medicines designed to damage or slow the growth of rapidly dividing cancer cells. In triple negative breast cancer, chemotherapy may be given before surgery, known as neoadjuvant chemotherapy, or after surgery, known as adjuvant chemotherapy. The timing can depend on the stage of the cancer and the goals of treatment.
Chemotherapy before surgery may help reduce the size of a tumor and allow healthcare professionals to assess how the cancer responds to treatment. Chemotherapy after surgery may be recommended to address cancer cells that may remain in the body but cannot be detected through standard tests.
Common considerations related to chemotherapy include:
Treatment for triple negative breast cancer continues to evolve as researchers study new medicines and combinations. Some individuals may also be eligible for clinical trials that investigate emerging treatment approaches. Regular communication with an oncology team can help patients understand the expected benefits, possible risks, side effects, and follow up requirements associated with their specific treatment plan.
Because every diagnosis is different, treatment decisions should be based on professional medical evaluation and the characteristics of the individual cancer. Reliable information and discussions with qualified healthcare professionals can help patients better understand triple negative breast cancer and the role chemotherapy may play in their overall care.